Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

基于价值的合同什么时候会增加价值? 来自概率模拟的洞察力

Rebecca K Metcalfe1, Karen Geary2, Mark Trusheim2

  • 1Core Clinical Sciences Inc., Vancouver, BC, Canada; Centre for Advancing Health Outcomes, University of British Columbia, Vancouver, BC, Canada.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
|March 28, 2025
PubMed
概括
此摘要是机器生成的。

概率模拟可以通过量化财务利益来简化基于价值的合同. 这些模拟有助于管理制造商和付款人之间的风险共享复杂性,以获得更好的结果.

关键词:
合同谈判 谈判 合同谈判药品制品制品制品制品制品制品制品制品统计模拟的统计模拟.基于价值的定价是基于价值的定价.

相关实验视频

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Evaluation of the Clinical Effectiveness and Cost-Effectiveness of Tirzepatide for Type 2 Diabetes in Canada Using Bayesian Transportability Analysis.

Value in health regional issues·2026
Same author

Anchoring convenience survey samples to a baseline census for vaccine coverage monitoring in global health.

Vaccine·2026
Same author

Logistical Challenges in Platform Randomized Trials - Operational Realities That Curb the Promise of Efficiency.

Clinical epidemiology·2026
Same author

Platform Trial Barriers-Why We Are Returning to Old Ways.

JAMA network open·2026
Same author

Estimands and their implications for evidence synthesis for oncology: A simulation study of treatment switching in meta-analysis.

Research synthesis methods·2026
Same author

Target Aggregate Data Adjustment Method for Transportability Analysis Utilizing Summary-Level Data From the Target Population.

Pharmaceutical statistics·2025
Same journal

Are preference-weighted cancer-specific measures more sensitive than generic measures? A comparison of EQ-5D-5L, SF-6Dv2, FACT-8D and QLU-C10D in gastrointestinal cancers.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Development and Validation of a Brief Healthcare Insecurity Scale in a Sample of U.S. Adults Living with and without HIV.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

A Competency Framework for Health Technology Assessment Expertise: Results from a Delphi Study.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Physician-led Switching from Reference Biologics to Biosimilars: What is the Effect on selected Health-Related Outcomes and Costs for IBD Patients in Germany?

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020-2023).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Interpreting the Economic Value of TPEx in Recurrent or Metastatic HNSCC: The Importance of Decision Context, Utility Timing, and Treatment Burden.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
查看所有相关文章

科学领域:

  • 卫生经济学 卫生经济学
  • 药品市场的准入 药品市场的准入
  • 生物统计学 生物统计学

背景情况:

  • 基于价值的合同 (VBC) 或基于结果的协议,将退款与患者的结果联系起来,在制造商和支付人之间提供风险共享.
  • 病毒细胞细胞的有限吸收部分归因于它们固有的复杂性.
  • 概率模拟提供了一种新的方法来简化VBC规划和财务评估.

研究的目的:

  • 探索概率模拟在促进基于价值的合同的规划中的实用性.
  • 根据治疗效果,折扣比例和患者数量来描述VBCs的净财务收益.
  • 评估模拟导向规划如何有助于谈判VBCs.

主要方法:

  • 模拟单个里程碑基于价值的合同,用于15或100名患者,每场景使用10,000次代.
  • 分析了来自不同规模 (30,100,500名患者) 的临床试验的二元治疗响应率 (50%,75%,90%).
  • 估计相当的贴现率和描述性比较的模拟结果.

主要成果:

  • 随着信息性的临床试验规模的减少,潜在的VBC结局范围越来越广.
  • 治疗的患者数量,而不是临床证据的不确定性,是潜在的折扣金额的主要驱动因素.
  • 模拟结果突出了支付人和制造商之间的差异性风险共享可能性.

结论:

  • 制造商可以从多个VBC与各种付款人的风险聚合中受益.
  • 虚拟银行涉及复杂的权衡和不确定性,可以通过模拟导向规划更好地管理.
  • 模拟工具可以量化财务利益,帮助谈判和采用VBCs.